MIRA INFORM REPORT

 

 

Report Date :

08.10.2013

 

IDENTIFICATION DETAILS

 

Name :

LA QUIMICA FARMACEUTICA S.A.

 

 

Registered Office :

Avda.Primer Presidente 1736 y calle Yrendague, Asuncion

 

 

Country :

Paraguay

 

 

Year of Establishments:

1943

 

 

Legal Form :

Public Limited Company

 

 

Line of Business :

Development and marketing of drug for use human.

 

 

No. of Employees :

Not Available 

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate  

 

 

Payment Behaviour :

Unknown

 

 

Litigation :

Clear 

 


 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Paraguay

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

PAraguay ECONOMIC OVERVIEW

 

Landlocked Paraguay has a market economy distinguished by a large informal sector, featuring re-export of imported consumer goods to neighboring countries, as well as the activities of thousands of microenterprises and urban street vendors. A large percentage of the population, especially in rural areas, derives its living from agricultural activity, often on a subsistence basis. Because of the importance of the informal sector, accurate economic measures are difficult to obtain. On a per capita basis, real income has stagnated at 1980 levels. The economy grew rapidly between 2003 and 2008 as growing world demand for commodities combined with high prices and favorable weather to support Paraguay's commodity-based export expansion. Paraguay is the sixth largest soy producer in the world. Drought hit in 2008, reducing agricultural exports and slowing the economy even before the onset of the global recession. The economy fell 3.8% in 2009, as lower world demand and commodity prices caused exports to contract. The government reacted by introducing fiscal and monetary stimulus packages. Growth resumed at a 13% level in 2010, the highest in South America, but slowed to about 4% in 2011 as the stimulus subsided. In 2012, severe drought and outbreaks of foot-and-mouth disease led to a drop in beef and other agricultural exports and the economy contracted about 0.5%. Political uncertainty, corruption, limited progress on structural reform, and deficient infrastructure are the main obstacles to long-term growth.

 

Source : CIA

 

 

 

 

Registered name

 

LA QUIMICA FARMACEUTICA S.A.

"QUIMFA"

RUC. 800024230

 

 

Summary 

 

BEGINNER OF ACTIVITIES. INCORPORATED IN 1943. NOT PROVIDED BALANCE SHEET. NO NEGATIVE. FIT FOR OPERATIONS OF MODERATE IMPORTANCE WITH ADEQUATE GUARANTEES.

 

 

Operations 

 

DEVELOPMENT AND MARKETING DRUG FOR USE HUMAN.

 

 

Legal Structure 

 

LEGAL FORM:                          PUBLIC LIMITED COMPANY
CREATED:                                1943
REGISTERED RPC:                  1943
DURATION:                               UNLIMITED
END OF FISCAL YEAR:            31.12

 

 

Contact 

 

Legal and dependences operatives address: Avda.Primer Presidente 1736 y calle Yrendague, Asuncion, Republic of Paraguay.

Phone. 595.21 222391
Fax.     595.21 224791
E.Mail:              quimfa@quimfa.com.py
                       lorenzobritel@quimfa.com.py
Website:           www.quimfa.com.py    

 

 

Partners 

 

OSCAR LUIS RAMIREZ (Commercial Manager).

Personal Information 

 

OSCAR LUIS RAMIREZ:
-------------------
Is Doctor Bioquimico, graduated from the Faculty of Medical Sciences and before joining the company holding served as Marketing Manager in the social reason LABORATORIOS ETICOS S.A. and Manager in HOECHST MARION ROUSSE PARAGUAY.

 

 

History 

 

It has been determined through the inquiries that have been made, that the activities in question were initiated and implemented by this society, which governs their actions by legal clauses mentioned above.

It is a pharmaceutical company for the category with 70 years in the domestic market, being located in the city of Asuncion in the Republic of Paraguay.

It has an installed manufacturing plant in Trinidad, Asuncion, Paraguay, which is dedicated to the preparation of solid pharmaceutical products, injections, oral liquid forms of syrups, drops, suspensions and semosolidos in forms of creams, ointments, gels with active general non-beta-lactams.

The infrastructure and implemented quality system allows you to export medicines to several countries of Latin America.

 

 

Economic-Financial Position 

 

At company premises our agent was attended by Mr. LORENZO BRITES, administrative department official, not is provided any kind of finance information.

 

 

Assets 

 

REAL ESTATE:
------------
Avda.Primer Presidente 1736 y calle Yrendague, Asuncion, Republic of Paraguay.
Surface of 20.000 m2 and covered surface of 10.000 m2.

 

 

Evolution and Results 

 

The society is devoted to the activities mentioned above, with appropriate operational structure, in which many employees play in the care of different tasks, under the direct supervision of their primary responsibility.

The products are developed under international standards so as to ensure the strictest vigilance over the quality and safety of the same.

Among the products it produces, markets and exports may be mentioned the following:

- A 3 COMPUESTO
- A 3 COMPUESTO N.F.
- AAS 100
- AAS 125
- AAS 325
- AAS 500
- AAS 81
- ACIDO FOLICO 10 MG NOVOPHAR
- ACIDO FOLICO 30 MG NOVOPHAR
- ACIDO FOLICO 05 MG NOVOPHAR
- AEROFAGIL 200
- AEROFAGIL AMPOLLAS BEBIBLES
- AEROFAGIL EMULSION
- AEROFAGIL GOTAS
- AFOLIC 10 MG
- AFOLIC 01 MG
- AFOLIC 05 MG
- AFONITOL CHERRY
- AFONITOL EUCALIPTO
- AFONITOL MENTOLADO

 

 

Payment Record and Credit Risk 

 

HSBC BANK
BANCO CONTINENTAL
BBVA PARAGUAY

Centralhouse.

INSURANCE:
----------
MAPFRE S.A.

 

 

Concept 

 

Recent investigations have determined that it is canceling the obligations assumed in terms classified as normal and is well referenced.

*  NOT OBJECTIONS.

 


Final Opinion 

 

It concludes that operations could relate to this society credit within sums of moderate importance in practical conditions.

At higher levels of consideration, it is advisable to seek appropriate guarantees.

* SUITABLE FOR CREDITS.


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.61.78

UK Pound

1

Rs.99.06

Euro

1

Rs.83.84

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.